Adenocarcinoma of the Pancreas

Fanta, Paul T.; Lowy, Andrew M.

doi:10.1002/9781118512074.ch87

Cited by 1 publication

(1 citation statement)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The histopathological progression from premalignant lesions (cystic mucinous neoplasia, intrapapillary mucinous neoplasia, pancreatic intraepithelial neoplasia, or intraductal oncocytic neoplasia) to PDAC is mediated by complex interactions that involve genetic mutations, modifications of the tumoral microenvironment, tumoral immunoediting, neoangiogenesis, and alterations in signaling pathways [4,5].…”

Section: Introductionmentioning

confidence: 99%

Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma

Dobre

Herlea

Vlăduţ

et al. 2021

Cells

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC), the most prevalent neoplastic lethal pancreatic disease, has a poor prognosis and an increasing incidence. The insulin-like growth factor-1 receptor (IGF-1R) signaling pathway is considered to be a contributing factor to the progression, metastasis, and therapy resistance of PDAC. Currently available treatment options for PDAC are limited, but microRNAs (miRNAs) may represent a new therapeutic strategy for targeting genes involved in the IGF-1R signaling pathway. Method: We investigated the expression levels of 21 miRNAs involved in the IGF-1R signaling pathway in pancreatic tissue from 38 patients with PDAC and 11 controls (five patients with chronic pancreatitis and six patients with normal pancreatic tissue). Results: We found 19 differentially expressed miRNAs between the PDAC cases and the controls. In particular, miR-100-5p, miR-145-5p, miR-29c-3p, miR-9-5p, and miR-195-5p were exclusively downregulated in PDAC tissue but not in chronic pancreatitis or normal pancreatic tissues; both control types presented similar levels. We also identified miR-29a-3p, miR-29b-3p, and miR-7-5p as downregulated miRNAs in PDAC tissues as compared with normal tissues but not with pancreatitis tissues. Conclusions: We identified a panel of miRNAs that could represent putative therapeutic targets for the development of new miRNA-based therapies for PDAC.

show abstract

Section: Introductionmentioning

confidence: 99%